Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy

Journal of Controlled Release

Volumn 122, Issue 1, 2007, Pages 31-38

  Etrych, Tomáš ^a   Mrkvan, Tomáš ^b   Říhová, Blanka ^b   Ulbrich, Karel ^a  

^a INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

Doxorubicin; Drug delivery systems; Drug release; Human immunoglobulin (HuIg); Water soluble polymers

Indexed keywords

DRUG DELIVERY; ONCOLOGY; PROTEINS;

DRUG DELIVERY SYSTEMS; HUMAN IMMUNOGLOBULIN (HUIG); WATER-SOLUBLE POLYMERS;

CONJUGATED POLYMERS;

DOXORUBICIN; IMMUNOGLOBULIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BLOOD PH; CANCER CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOSTASIS; DRUG CONJUGATION; DRUG RELEASE; DRUG SENSITIVITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULINS; LYMPHOMA, T-CELL; MALE; MICE; MICE, INBRED C57BL; POLYMETHACRYLIC ACIDS;

EID: 34548015449     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.06.007     Document Type: Article

References (27)

1. Schacht E.H., Vansteenkiste S., and Seymour L. Macromolecular carriers for drug targeting. In: Kostelnik R.J. (Ed). The Practice of Medicinal Chemistry (1996), Academic Press, New York 717-736
2. Ulbrich K., Šubr V., Strohalm J., Plocová D., Jelínková M., and Říhová B. Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. Synthesis and physico-chemical characterisation. J. Control. Release 64 (2000) 63-79
3. Říhová B., Jelínková M., Strohalm J., Šťastný M., Hovorka O., Plocová D., Kovář M., Drábelová L., and Ulbrich K. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and methastatic human colorectal carcinoma and on human colorectal carcinoma transfected with mouse Thy-1.2 gene. Bioconjug. Chem. 11 (2000) 664-673
4. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev., Cancer 6 (2006) 688-701
5. 2-targeted conjugates and combined therapy with immunomodulators. J. Control. Release 64 (2000) 241-261
6. Ulbrich K., and Šubr V. Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev. 56 (2004) 1023-1050
7. Garnet M. Targeted drug conjugates: principles and progress. Adv. Drug Deliv. Rev. 53 (2001) 171-216
8. Kopeček J., Kopečková P., Minko T., Lu Z.R., and Peterson C.M. Water soluble polymers in tumor targeted delivery. J. Control. Release 74 (2001) 147-158
9. Ulbrich K., Strohalm J., Šubr V., and Plocová D. Polymeric conjugates of drugs and antibodies for site-specific drug delivery. Macromol. Symp. 103 (1996) 177-192
10. Putnam D., and Kopeček J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122 (1995) 55-123
11. Haag R., and Kratz F. Polymer therapeutics: concepts and applications. Angew. Chem., Int. Ed. 45 (2006) 1198-1215
12. Kratz F., Beyer U., and Schutte M.T. Drug-polymer conjugates containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carr. Syst. 16 (1999) 245-288
13. Etrych T., Jelínková M., Říhová B., and Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release 73 (2001) 89-102
14. Etrych T., Chytil P., Jelínková M., Říhová B., and Ulbrich K. Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity. Macromol. Biosci. 2 (2002) 43-52
15. Říhová B., Etrych T., Pechar M., Jelínková M., Šťastný M., Hovorka O., Kovář M., and Ulbrich K. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J. Control. Release 74 (2001) 225-232
16. Mrkvan T., Šírová M., Etrych T., Chytil P., Strohalm J., Plocová D., Ulbrich K., and Říhová B. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity. J. Control. Release 110 (2005) 119-129
17. Vasey P.A., Kaye S.B., Morrison R., Twelves Ch., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Butrles S., Fraier D., Frigerio E., and Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 5 (1999) 83-94
18. Julyan P.J., Seymour L.W., Ferry D.R., Daryani S., Boivin Ch.M., Doran J., David M., Anderson D., Christodoulos Ch., Young A.M., Hesslewood S., and Kerr D.J. Preliminary clinical study of HPMA copolymers bearing doxorubicin and galactosamine. J. Control. Release 57 (1999) 281-290
19. Kovář M., Mrkvan T., Strohalm J., Ulbrich K., Etrych T., and Říhová B. HPMA copolymer-bound doxorubicin conjugate targeted to tumor specific antigen of BCL1 mouse B cell leukemia. J. Control. Release 92 (2003) 315-330
20. Jelínková M., Strohalm J., Etrych T., Ulbrich K., and Říhová B. Star-like versus classical macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs. Pharm. Res. 20 (2003) 1558-1564
21. Šírová M., Strohalm J., Šubr V., Plocová D., Rosman P., Mrkvan T., Ulbrich K., and Říhová B. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces systemic and long-lasting anti-tumor immunity in mice. Cancer Immunol. Immunother. 56 (2007) 35-47
22. Maeda H. The enhanced permeability and retention (EPR) effect in tumor asculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41 (2001) 189-207
23. Ulbrich K., Etrych T., Chytil P., Jelínková M., and Říhová B. HPMA copolymers with pH-controlled release of doxorubicin. In vitro cytotoxicity and in vivo antitumor activity. J. Control. Release 87 (2003) 33-47
24. Ulbrich K., Etrych T., Chytil P., Jelínková M., and Říhová B. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J. drug Target. 12 (2004) 477-489
25. Šubr V., Koňák È., Laga R., and Ulbrich K. Coating of DNA/poly(l-lysine) complexes by covalent attachment of poly[N-(2-hydroxypropyl)methacrylamide]. Biomacromolecules 7 (2006) 122-130
26. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 74 (1959) 443-460
27. Šubr V., Strohalm J., Ulbrich K., Duncan R., and Hume I.C. Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly-[2-(hydroxypropyl)methacrylamide] drug carriers in vitro and antitumour activity measured in vivo. J. Control. Release 18 (1992) 123-132